HOME >> MEDICINE >> NEWS
Treatment for ADHD appears to reduce risk of substance abuse

Boys with attention-deficit hyperactivity disorder (AHDH) who are treated with medications - usually stimulant drugs like Ritalin - are one-third as likely to develop substance abuse or dependence as are boys with ADHD who receive no treatment, according to a study from the Massachusetts General Hospital (MGH). The report in the August issue of Pediatrics contradicts a common fear that stimulant treatment could open the door to future drug abuse.

"Because the mainstay of ADHD treatment has been potentially addictive, stimulant drugs, there has been a mythology that the use of these medications could 'prime' children to become addicts in future or could develop a 'culture of drug taking'," says Joseph Biederman, MD, director of the MGH Pediatric Psychopharmacology Unit and lead author of the study. "We have found that the opposite is the case - children who are medically treated for ADHD have a smaller risk of drug abuse than do those who are not treated."

The current report is based on analysis of data from an earlier study that followed a group of more than 500 children for four years. The children and their mothers were inter-viewed on three occasions - when they first entered the study, one year later, and four years after enrollment - regarding symptoms of a variety of psychological and behavior problems. The children were categorized into three groups: those who met criteria for ADHD and reported having been treated with medication for the disorder, those meeting ADHD criteria who had received no treatment, and children not meeting criteria for ADHD.

In order that the three groups be as similar as possible, data was analyzed only from males who were 15 or older when entering the study, resulting in a study group of 56 medicated participants with ADHD, 19 non-medicated participants with ADHD, and 137 participants without ADHD. Results of the interviews were analyzed to determine whether participants met criteria for abuse of or dependenc
'"/>

Contact: Susan McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
2-Aug-1999


Page: 1 2

Related medicine news :

1. Treatment of cardiac lesions without anaesthesic
2. Treatment guidelines for kids with bipolar disorder published
3. University of Washington joins new Autism Treatment Network to provide better medical services
4. Treatment for brain tumor does not always follow recommendations
5. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
6. Treatment of ductal carcinoma in situ varies widely in United States
7. Treatment options expand for patients with neuropathic pain
8. Treatment interruption shows no benefit in drug-resistant HIV infection
9. Peanut Allergy: Major Advances in Treatment and Education
10. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
11. Treatment helped reduce dose of inhaled corticosteroids while maintaining asthma control

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Treatment for ADHD appears reduce risk substance abuse

(Date:5/20/2013)... Medicare Part D seniors in plans with preferred ... access to pharmacies and other benefits, according to a ... the Pharmaceutical Care Management Association (PCMA). More than 40% ... in plans with preferred networks. , “Seniors like the ... with preferred pharmacy networks,” said PCMA President and CEO ...
(Date:5/20/2013)... A new Benefits of Pharmacy Home Delivery report ... MedEx Pack announced. The new report offers ... order to provide useful details for those who are contemplating ... MedEx Direct owner and pharmacist said, “One of the biggest ... like the MedEx Pack, patients can receive their own pre-filled ...
(Date:5/20/2013)... new report suggests that improved health care and significant ... up the age-old relationship between physicians and drug company ... unnecessary prescription drugs. , This system, which has been ... by keeping them up to date on new medications, ... get patients started on the newest drugs, as well ...
(Date:5/20/2013)... GA (PRWEB) May 20, 2013 ... nominations for this year’s prestigious Information Security Executive® ... , Awards include the Information Security Executive® ... which recognize executives who have made a positive ... protection, regulatory compliance, privacy and information security; and ...
(Date:5/20/2013)... 20, 2013 Selexis SA, a serial ... and cell line development for scale-up and manufacturing of ... will present data on the Company’s core technology at ... Conference, May 20 - 23 at the Hyatt Regency ... co-founder and scientific advisory board member, Nicolas Mermod, PhD, ...
Breaking Medicine News(10 mins):Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 3Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3
(Date:5/20/2013)... , May 20, 2013  AbbVie (NYSE: ... of a Phase 3 clinical study called SONAR ... the effects of the investigational compound atrasentan - when ... kidney disease in patients with stage 2 to ... diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled ...
(Date:5/19/2013)... May 20, 2013  Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
Cached News: